Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + oxaliplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Tislelizumab + oxaliplatin + capecitabine is a combination regimen used primarily for the treatment of advanced or metastatic gastric and gastroesophageal junction adenocarcinoma, as well as other gastrointestinal cancers. Tislelizumab is a monoclonal antibody that targets programmed cell death protein 1 receptor (PD-1), blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune responses. Oxaliplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking, leading to apoptosis in rapidly dividing cells. Capecitabine is an oral prodrug of 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis in cancer cells. The combination leverages both immunotherapy and cytotoxic chemotherapy mechanisms to improve clinical outcomes in patients with HER2-negative, unresectable or metastatic disease[1][5][8].
- Brand names
- Tevimbra (tislelizumab)Xeloda (capecitabine)Eloxatin (oxaliplatin)
- Other names
- XELOXCapeOx
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on tislelizumab + oxaliplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + oxaliplatin + capecitabine.